Gene therapy trial targets Huntington's disease in 5 patients
NCT ID NCT05541627
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 31 times
Summary
This early-stage trial tests a gene therapy called AB-1001 in 5 adults with early Huntington's disease. The therapy is injected directly into the brain to try to slow the disease. The main goal is to check safety and side effects, while also looking at brain changes on MRI scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut du Cerveau (ICM), Hôpital La Pitié Salpêtrière APHP
Paris, Île-de-France Region, 75013, France
Conditions
Explore the condition pages connected to this study.